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DINOFI
T° fight both old and new diseases, sci-
l entists search continually for new
pharmaceuticals. Many new drugs may
soon come from compounds produced by
marine animals and plants, and the great
diversity ofmarine organisms could poten-
tially lead to an equally diverse array of
drugs. David Newman, a chemist in the
natural products branch of the National
Cancer Institute, explains the interest in
marine compounds by considering a coral
reef. "On a coral reef," he says, "the only
way that an organism can survive is if it
has a foothold, or toehold, because these
[organisms] are almost all filter feeders.
Therefore, if you have two sponges sitting
alongside each other, you will occasionally
see a demarcation line, almost as if they
come up to each other and stop. Basically
what you've got is chemical warfare going
on there. You've got a quest for space, and
as you go in and start looking you find
some absolutely fascinating chemistry."
That chemistry might produce equally fas-
cinating pharmaceuticals.
Coral reef organisms alone may soon
spawn a variety of new drugs. For example,
the plant-like bryozoan Bugula neritina
produces a compound called bryostatin 1,
which is in Phase II clinical trials as an
agent against melanoma, lymphoma, and
nephroma. Dolabella auricularia, a type of
nudibranch, or shell-less mollusk, makes
dolastatin 10, an agent that looks promis-
ing against cancer. Beyond coral reefs, sim-
ilar potential may exist in other marine
organisms. In fact, thousands of com-
pounds have been isolated from marine
organisms in the past two decades.
Although
vast ocean w
host thousands o
tially powerful dru,isms that
make them can be so rare or inaccessible
that scientists cannot collect and test the
compounds. Says Yuzuru Shimizu, a nat-
ural-products chemist at the University of
Rhode Island in Kingston, "A lot of com-
pounds have been isolated from marine
animals, and they are very interesting com-
pounds. Many of them probably have the
potential to become drugs. The drawback
is that they are found only in very minute
quantities. Also, the animals can be scarce
and it is not easy to collect large quantities
to isolate enough material to do some pre-
liminary tests." Shimizu hopes to farm
these organisms through large-scale aqua-
culture so that pharmaceutical companies
can harvest as much of a compound as
needed.
Drugs from Dinoflagellates
In 1970, Shimizu began studying bioactive
metabolites ofmicroalgae. He tested some
ofthe compounds for their pharmaceutical
potential by screening them against cancer-
ous cell lines in tissue culture. Such screen-
ing tests sparked Shimizu's interest in
dinoflagellates, or single-celled phyto-
plankton.
To determine what compound is pro-
duced by a specific dinoflagellate, Shimizu
needed a culture that included only that
organism. To prepare such a culture,
Shimizu first collected organisms from the
ocean. Then, using a micropipette, he
hand-selected a single dinoflagellate under
LA
a microscope. That organism was cultured
and allowed to multiply. As the organism's
numbers increased, the culture was moved
from a tiny well that held a few drops of
seawater to a container the size of a test
tube, and then to an even larger container.
The culture was also treated to eliminate
other microorganisms. The end result of
the procedure was a culture composed of a
single species, with no contaminants.
Once Shimizu had a pure culture, he
looked for compounds. He took as many
dinoflagellates as he could get from a cul-
ture, ground them up, and tried to extract
individual compounds. Using various
forms of chromatography, Shimizu sepa-
rated the homogenized dinoflagellates into
chemical samples. These samples were run
through more chromatographic procedures
and further purified in hopes ofisolating a
single compound. In collaboration with
Shimizu, Bristol-Myers Squibb tested the
compounds for their potential in fighting
cancer. Unpublished results showed that
one compound, carbenolide-I, shrank
tumors when tested in vivo in mice with
leukemia.
IsolatingAmphidinolide
After a collecting trip near St. Thomas in
the Caribbean, Shimizu started culturing a
dinoflagellate of the genus Amphidinium.
He and his colleagues worked for two
years, growing batch after batch of
Amphidinium in 150-liter tanks.
Eventually, Shimizu had 6,000 1 ofculture.
From that, he isolated 50 mg of a com-
pound called amphidinolide B.
This compound stirred great interest.
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In 1993, Jun'ichi Kobayashi and Masami
Ishibashi, both pharmacologists at
Hokkaido University in Japan, wrote in
Chemical Reviews, "It should be noted that
the cytotoxic activity of amphidinolide B
and its related compounds are extremely
strong." In particular, they reported that
amphidinolide B killed cultures ofa mouse
leukemia cell line and a human carcinoma
cell line. Consequently, Shimizu saw the
potential of this compound, but he says
that 50 mg was "not enough to do any fur-
ther biological tests. So we had to get much
larger quantities." He adds that there are
20-30 other interesting compounds pro-
duced by Amphidinium, but they are even
scarcer in this dinoflagellate. For example,
he obtained 10 mg ofcarbenolide-I, which
he says is an anticarcinogen 100 times more
potent than amphidinolide.
Cranking up the Culturing
After taking two years to make 6,000 1 of
Amphidinium culture, Shimizu knew that
he needed to increase the scale of his cul-
turing. To do that, he turned to his own
backyard, the Marine Ecosystems Research
Laboratory at the University of Rhode
Island, which includes 14 culture tanks,
each capable ofholding 15,000 1.
These cylindrical fiberglass tanks-5.5
m tall and 1.8 m in diameter-were origi-
nally designed for environmental studies.
Consequently, they include computer con-
trols for temperature, lighting, stirring, and
other variables. Lucie Maranda, a marine
research scientist at the University of
Rhode Island's Graduate School of
Oceanography, explains that it takes
15-20 carboys-each containing 12 1 of
Amphidinium culture-to inoculate one of
the large tanks. Then, she says, it takes 6-8
weeks to go from inoculation to harvest,
depending on the species being cultured.
Once a culture reaches maturity-
essentially multiplying to a high density-
the dinoflagellates are harvested. First,
Shimizu and colleagues add alum, or
potassium aluminum sulfate, to a tank to
make the dinoflagellates group together
and sink to the bottom. Then the upper
liquid can be pumped off, leaving a slurry
of organisms and alum at the bottom of
the tank. This mixture goes into a device
much like the one that separates cream
from milk. In this case, though, the device
separates the dinoflagellates from the slur-
ry. The end product-dinoflagellates-can
be used to isolate compounds.
Shimizu says, "The large culture [sys-
tem] is a completely new game." In this
new approach, even the chemistry of the
organism changes; they make metabolites
at different times in their development. So
Shimizu and his colleagues
must now analyze the
metabolic products
throughout Amphidinium's
development in these large
cultures. Shimizu says,
"We have shown that we
can grow this organism in
large quantities. That, we
feel, is a great accomplish-
ment. We opened a way
that we can procure, if
necessary, a large amount
ofcompound."
Shimizu succeeded in
combining large-scale cul-
turing with many types of
chromatography to isolate
the pure compound. Jon
Clardy, a professor of
chemistry at Cornell
University in Ithaca, New
York, says, "It's hard
enough to get mixtures of
amphidinolides. And it's
even harder to get one
pure.
Nevertheless, Clardy
says, "Yuzuru was able to
purify one. That's what he
does better than anyone
else. A number of people
had worked on the
amphidinolides, but he was
A lot of Amphidinium. Huge 15,000
liter culture tanks allow researchers
enough dinoflagellate to isolate the
minute amounts of cancer-fighting
compounds they contain.
the one who pulled out a pure compound
so that it could be studied." Using that
purified amphidinolide B, Clardy and his
colleagues determined its structure by X-
ray diffraction. The structure includes an
enormous ring composed of 25 carbon
atoms and one oxygen atom. Clardy says
that knowing a compound's structure
allows a chemist to consider synthesizing
or modifying it.
Starting a Synthesis
Pharmaceutical companies synthesize com-
pounds so that they can be made artificial-
ly to ensure a constant supply. A com-
pound may also need to be synthesized or
modified because, Newman says, "It is very
rare that a material directly isolated from a
natural source is the
drug in the end. In gen-
eral, what you get is
either a structure that
you then modify or
information that allows
you to make something
similar but slightly dif-
ferent." A chemist can
make those modifica-
tions through synthesis,
building the compound
from scratch. David
Myles, a synthetic
organic chemist at the
University of California
at Los Angeles, and his
colleagues may soon
synthesize amphidino-
lide B.
Hugo Eng, a gradu-
ate student of Myles's,
has been attacking this
synthesis problem
through a convergent
synthetic strategy, trying
to make amphidinolide
B from relatively large
starting pieces. Still, Eng
must synthesize the
starting pieces-essen-
tially quarters of the
total compound that are
similar in size and com-
plexity-atom by atom. So far, he has syn-
thesized all four pieces. He has also cou-
pled different pieces together. To complete
the synthesis he must couple all four com-
ponents and, finally, close the structure's
large ring.
Myles believes that synthesis and
aquaculture complement each other. He
says, "All of the information in the data-
base we've built up on amphidinolides in
our total synthesis would, in some way, be
applicable to semisynthesis; in otherwords,
modification ofa natural product."
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